BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29869564)

  • 1. Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Stat Methods Med Res; 2019 Jun; 28(6):1852-1878. PubMed ID: 29869564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of the effect size for sample size determination for a continuous response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD; Peduzzi PN
    Clin Trials; 2016 Jun; 13(3):275-85. PubMed ID: 26928986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of the treatment effect for sample size determination in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD; Makuch RW; Peduzzi PN
    Contemp Clin Trials; 2015 Mar; 41():160-71. PubMed ID: 25583273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian sample size re-estimation using power priors.
    Brakenhoff TB; Roes K; Nikolakopoulos S
    Stat Methods Med Res; 2019 Jun; 28(6):1664-1675. PubMed ID: 29717945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size re-estimation incorporating prior information on a nuisance parameter.
    Mütze T; Schmidli H; Friede T
    Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size reestimation and Bayesian predictive probability for single-arm clinical trials with a time-to-event endpoint using Weibull distribution with unknown shape parameter.
    Waleed M; He J; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):469-487. PubMed ID: 37545144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
    Gordon Lan KK; Wittes JT
    Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive power.
    Liu Q; Hu G; Ye B; Wang S; Wu Y
    Pharm Stat; 2023 Mar; 22(2):349-364. PubMed ID: 36418025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blinded sample size re-estimation in three-arm trials with 'gold standard' design.
    Mütze T; Friede T
    Stat Med; 2017 Oct; 36(23):3636-3653. PubMed ID: 28608469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The perils with the misuse of predictive power.
    Dallow N; Fina P
    Pharm Stat; 2011; 10(4):311-7. PubMed ID: 20967762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid classical-Bayesian approach to sample size determination for two-arm superiority clinical trials.
    Sambucini V
    Int J Biostat; 2024 Jul; ():. PubMed ID: 38943460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size re-estimation in a breast cancer trial.
    Hade EM; Jarjoura D; Lai Wei
    Clin Trials; 2010 Jun; 7(3):219-26. PubMed ID: 20392786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On sample size estimation and re-estimation adjusting for variability in confirmatory trials.
    Wu PS; Lin M; Chow SC
    J Biopharm Stat; 2016; 26(1):44-54. PubMed ID: 26378970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epistemic uncertainty in Bayesian predictive probabilities.
    Liu CC; Yu RX
    J Biopharm Stat; 2024 May; 34(3):394-412. PubMed ID: 37157818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blinded sample size re-estimation in superiority and noninferiority trials: bias versus variance in variance estimation.
    Friede T; Kieser M
    Pharm Stat; 2013; 12(3):141-6. PubMed ID: 23509095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.
    Hade EM; Young GS; Love RR
    Trials; 2019 Aug; 20(1):527. PubMed ID: 31443726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.